- Home
- NSPR vs IMUX Comparison
NSPR vs IMUX Comparison
Compare NSPR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- IMUX
- Stock Information
- Founded
- NSPR 2005
- IMUX 2016
- Country
- NSPR United States
- IMUX United States
- Employees
- NSPR N/A
- IMUX N/A
- Industry
- NSPR Medical/Dental Instruments
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- IMUX Health Care
- Exchange
- NSPR Nasdaq
- IMUX Nasdaq
- Market Cap
- NSPR 75.1M
- IMUX 67.8M
- IPO Year
- NSPR N/A
- IMUX N/A
- Fundamental
- Price
- NSPR $2.44
- IMUX $0.83
- Analyst Decision
- NSPR Strong Buy
- IMUX Strong Buy
- Analyst Count
- NSPR 2
- IMUX 6
- Target Price
- NSPR $4.50
- IMUX $11.60
- AVG Volume (30 Days)
- NSPR 386.2K
- IMUX 1.6M
- Earning Date
- NSPR 08-05-2025
- IMUX 08-07-2025
- Dividend Yield
- NSPR N/A
- IMUX N/A
- EPS Growth
- NSPR N/A
- IMUX N/A
- EPS
- NSPR N/A
- IMUX N/A
- Revenue
- NSPR $7,027,000.00
- IMUX N/A
- Revenue This Year
- NSPR $4.85
- IMUX N/A
- Revenue Next Year
- NSPR $113.47
- IMUX N/A
- P/E Ratio
- NSPR N/A
- IMUX N/A
- Revenue Growth
- NSPR 8.49
- IMUX N/A
- 52 Week Low
- NSPR $1.99
- IMUX $0.56
- 52 Week High
- NSPR $3.80
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- NSPR 54.16
- IMUX 55.91
- Support Level
- NSPR $2.12
- IMUX $0.68
- Resistance Level
- NSPR $2.46
- IMUX $0.83
- Average True Range (ATR)
- NSPR 0.16
- IMUX 0.05
- MACD
- NSPR 0.01
- IMUX 0.02
- Stochastic Oscillator
- NSPR 73.33
- IMUX 88.50
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.